相关实验视频
Updated: May 10, 2025
09:42
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
Published on: June 4, 2021
2.6K
关于因子XII在缺血性中风中介导的血栓炎症机制的研究进展
Han Liu1,2, Kailin Yang1,3, Shanshan Wang4,5
1Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, Changsha, China.
Journal of thrombosis and thrombolysis
|April 25, 2025
概括
凝血因子XII (FXII) 在缺血性中风 (IS) 病理学中发挥着双重作用. 了解其复杂的结构和来自神经元的神经保护作用是开发有效的IS疗法的关键.
科学领域:
- 神经科学是一个神经科学.
- 血液学 血液学 血液学
- 病理生理学 病理生理学
背景情况:
- 缺血性中风 (IS) 是导致死亡和残疾的主要原因,由血栓炎症驱动.
- 凝血因子XII (FXII) 参与IS的发病,作为治疗点.
- 矛盾的临床观察阻碍了FXII向治疗的转化.
研究的目的:
- 审查IS中FXII复杂的监管机制.
- 阐明FXII的结构和空间异质性及其独特的生物效应.
- 强调FXII的特定领域功能和神经保护作用.
主要方法:
- 文献综述,重点关注在IS中的FXII结构,分布和功能.
- 对针对FXII的向疗法的临床前和临床数据的分析.
- 检查FXII在血栓炎症,神经炎症和血管重塑中的作用.
主要成果:
- 由于结构异质性 (来自肝脏的全长异形与来自神经元的异形),FXII表现出功能复杂性.
- 肝脏衍生的FXII有助于神经炎症和血管损伤.
- 神经元衍生的FXII通过HGF信号表现出神经保护作用;循环的FXIIa促进了血管重塑.
结论:
- FXII在IS中的多方面的作用需要一个细微的治疗方法.
- 针对FXII需要考虑其独特的异构和组织特异性功能.
- 神经元衍生的FXII为IS治疗中的神经保护策略提供了一个有前途的途径.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
545
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
545
01:20Extrinsic and Intrinsic Pathways of Hemostasis
3.6K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
3.6K
01:16Clot Retraction and Fibrinolysis
2.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
2.5K
01:22Formation of the Platelet Plug
2.8K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
2.8K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
388
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
388
01:09Coagulation
3.2K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
3.2K